How many acquisitions has GSK made so far?

GSK has completed 25 acquisitions so far, with an average acquisition amount of $1.57B.

Which countries does GSK usually acquire in?

GSK has made acquisitions in 7 countries with the most activity in United States and Canada.

Which is GSK's latest acquisition?

GSK's most recent acquisition is Nuvalent, a Developer of therapeutic solutions for the treatment of cancer, acquired in June 2026.

Which sectors does GSK target for acquisitions?

Most of GSK's acquisitions are in Immunotherapy (8) and Oncology (8).

List of 25 Acquisitions by GSK (Oct 2026)

GSK has made a total of 25 acquisitions. These activities span 14 sectors, including Oncology, Immunotherapy, and Infectious Diseases, across 7 countries, with significant activity in United States, Canada, and Switzerland. Peak acquisition years were 2026 and 2022, with 3 acquisitions each, and 2024, with 2 acquisitions. Between 2020 and 2025, the average number of acquisitions per year was 1.4, and 3 acquisitions have been completed in the current calendar year. The most recent acquisition is Nuvalent, a Cambridge-based developer of cancer therapeutic solutions founded in 2017; this acquisition took place in June 2026.

Here's the year on year acquisition history of GSK:

Number of Total Acquisitions

Year	# Acquisitions
2026	3
2025	1
2024	2
2023	1
2022	3
2018	1
2015	1
2013	1
2012	2
2010	2
2009	2
2008	2
2007	1
2006	2
2005	1

View all Acquisitions by GSK

Recent acquisitions by GSK

GSK's most recent acquisition - Nuvalent is a Developer of therapeutic solutions for the treatment of cancer, founded in 2017 and located in Cambridge. GSK acquired it in June 2026 for a price of $*****.

Here is the list of all acquisitions by GSK sorted by the latest acquisition date:

Acquired on	Acquired Company	Acquisition Price	Facilitators	Stake Acquired	Acquisition Multiple
Jun 09, 2026	Nuvalent	eyg{	y{rl	70	599
Feb 25, 2026	35Pharma	g{zt	euim	89	267
Jan 20, 2026	RAPT	qvlh	jbgw	39	342
Jan 08, 2025	IDRx	fxum	bkhx	18	675
Jun 06, 2024	Elsie Biotechnologies	xfht	nkbb	58	351